Tuesday, August 12, 2014

Zenosense, Inc. (ZENO) Sees the Potential in Cancer Sensory Devices

There are substantial costs associated with the late discovery of the MRSA (or Methicillin-resistant Staphylococcus aureus) super-bug and other hospital-acquired infections. In the US alone, there are the challenges posed to patients and healthcare providers, including tens of thousands of invasive infections and deaths and billions in treatments costs.

Spanish-company Zenosense strongly believes it has identified a lucrative new market segment as there is no existing, cost-effective system to serve as a “smoke alarm” for MRSA/SA with the purpose of detecting infection early in patients or the rooms of a healthcare building. To answer this largely unmet need, Zenosense has entered into an exclusive global license agreement with Sgenia Group to develop an effective detector for MRSA/SA, and Sgenia has established a new, dedicated subsidiary for the project: Zenon Biosystem.

Zenon is contracted, on a phased basis, to produce this sophisticated device, which will be based on an algal/water sensor platform that already exists. At this point, the plan is to use a single, commercial “off-the-shelf” gas sensor to sample the air and continuously monitor for the airborne volatile organic compounds (VOCs) signature emitted by MRSA/SA. The MRSA/SA VOC signature is only emitted when the bacteria has infected and presented itself as a disease in the patient. It can be detected prior to the patient being obviously symptomatic, enabling an earlier intervention.

Zenosense has made progress since the development of its MRSA device began in December of 2013. As of May 2014, it extended its development and exclusive license agreement with Sgenia to include cancer sensory devices. Under the terms of the extension, Zenosense has the option of funding the development of prospective cancer sensory devices that may be based on the Sgenia technology. Assuming it finances the project, Zenosense will have the right to manufacture, market, and sell any resulting devices that are developed.

Zenosense believes the sensory technology and algorithmic processing in development for MRSA detection could, if successful, be applied to certain cancer sensory devices. Some cancers, such as lung and colon, produce volatile organic compounds in an individual’s breath in a similar way that MRSA does. If the cancer-specific pattern of VOCs can be identified, Zenosense believes that a fairly-straightforward alteration of a successful MRSA detection technology may enable it to create a similar device for the exposure of certain cancers.

As with the MRSA/SA detector it has under development, Zenosense believes there could be huge demand for a relatively minimal-cost, rapid-detection device for these types of cancer. Such a device could allow for much wider screening and the ability to detect, for example, lung cancer at a much earlier stage and on a mass scale. Presently, lung cancer is usually detected at a late stage when fewer than 25% of cases can be cured; however, if detected in Stage I, there is a 70% cure rate.

For more information, visit www.zenosense.net

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.

Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net

The Quality Stocks Daily Blog http://blog.qualitystocks.net

The Quality Stocks Daily Videos http://videocharts.qualitystocks.net

The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net


Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net

No comments: